Former insights into pathophysiology and treatment of Nephrotic syndrome: A short review

Bhoomi B. Joshi and Kinnari N. Mistry*

Ashok & Rita Patel Institute of Integrated Studies in Biotechnology & Allied Sciences (ARIBAS), New Vallabh Vidhya Nagar-388121 (Gujarat) India

Abstract

Nephrotic syndrome (NS) is a chronic kidney disorder, distinguished by modifications of glomerular filtration barrier, resulting in its incapability to control the urinary protein loss. NS is a pathological entity identified by massive proteinuria which can lead into mortal infections, thrombosis, and edema due to significant protein loss. Information about principal cause of a syndrome is necessary for accepting its mechanism and for its sufficient classification, prediction, and management. Currently, the etiologies of NS have been revealed due to various acquired as well as genetic defects and its progressive forms can lead to chronic and end-stage renal disease. Foremost breadth of view about pathophysiology and treatment of Nephrotic syndrome are reviewed.

Introduction

During of the 20th century attempts were made in the medical literature to distinguish nephrosis (i.e. kidney disease distinguished by exudation and proliferation) from nephritis (i.e. nephritis). But, when it was noticed that nephrosis is neither a single disease, nor a group of related diseases, the word "nephrosis" was replaced by "nephrotic syndrome"[1]. Clinically nephrotic syndrome (NS) features develops into rigorous proteinuria, hypoalbominemia, edema and hypercholesterol conditions. These circumstances are closely related to foremost structural and morphological changes in glomerular epithelial cells, also named as "podocytes". Podocytes are extremely specific cells with abundant foot processes that cover up the external aspect of the glomerular basement membrane (GBM). One of the vital purposes of kidney for the period of prime urine formation is ultrafilteration of plasma protein. Ordinary filtration task of the glomerulus relay on the structural and functional reliability of the filtration barricade, that is the chief target of numerous innate and acquired glomerular dysfunctions, distinguished by nephrotic syndrome (greater than 3.5 g protein per day) and swift development to end stage renal disease (ESRD)[2]. In the primary NS of size around 60-280 KDa plasma proteins are lost that makes remarkable changes in plasma protein level. Etiology says, NS is caused due to two main reasons (1) acquired (due to toxins or infection), and (2) genetics[3]. The total ontonic pressure and plasma protein level decides the secondary effects of NS, where plasma protein level goes up to 750g/l causing extension in plasma volume. In NS, there is thickening of the foot process, but the remaining of the cell generally is conserved[4]. Endothelial cells possess many outlets that are 65 to 95 nm in diameter, called fenestrae, which form a substantial barrier for passageway of macromolecules from plasma into the renal tubule. Electron microscopy information leads to the recognition of negatively charged particles in the GMB, which prevent the passage of anionic macromolecules like

* *Corresponding Author: kinnarimistry@aribas.edu.in*

albumin[5].

Epidemiology

NS can influence any age group, both children and adults as primary or secondary form of which 62% to 80% are glomerulonephritis cases, where as others are of secondary nephropathy. In US, occurrence of NS is 3-4 cases per 100,000 children per year[8]. Increasingly this has been gone up to 16 cases per 100,000 children. When compared it has been found more frequent among boys than girls of juvenile age groups, but once they reach at puberty there is no such noteworthy difference among genders. NS has been more frequently observed at the age of 2-14 among children. Research proved Enlarged prevalence and extreme disease condition in African American and Hispanic populations[6]. There are also differences in epidemiology between the colours, the disease is more general in black than in white by a ratio of 2 to 1.The incidence data also states knowledge related to the majority widespread way that symptom develops in patients with NS as unprompted remission happens in up to 25% to 35% of cases during the initial year of the illness[7]. On the other hand, this improvement is not classic as some 55% to 65% of patients dies and / or expand to unrelieved renal failure 7 to 14 years after this remission. The main causes of death are cardiovascular, as a result of the chronicity of the syndrome, and thromboembolic accidents[8].

Pathophysiology

In NS, the pathophysiology of normal glomerular filtration function is strongly interrupted, resulting in severe-range proteinuria and hypoalbumina conditions. Reports showed role of immune pathogenesis where defect in T-Cell occurs through various circulating factors such as cytokines and other molecules[9,10]. On the whole, the glomerular filtration barrier is made of three consecutive layers, scheduled from capillary side to bowman's space side: Fenestrated endothelium negatively charged basement membrane to prevent the passage of large anionic molecules, visceral epithelial called as podocytes, which contains small pores with a fixed size with radius of around 30 to 50 amperes connecting adjacent foot processes are bridge by slit diaphragms and further maintain structural and function integrity of GMB[11]. In NS, the glomeruli are unable to filter back. NS pathophysiology revel protenuria, here the glomeruli are affected by inflammation or hyalinization and are unable to filter back albumin or other immunoglobulins back into blood rather these molecules pass through the membrane and are found in urine. Albumin is the major blood protein that regulates plasma ontonic pressure which causes increase in hepatic lipoprotein and transcapillary water level which later on causes the hyperlipidemia and edima conditions linked with NS. The actual mechanism by which this glomerular membrane gets damaged in primary and secondary disease is unknown, but reports chains the role of T-cells in up regulating circulating factors or down regulating inhibitory factors in reaction to unrevealed immunogens and cytokines[12].

Other probable facts involved in pathophysiology of NS can be either hereditary defect in proteins that are essential to the slit diaphragms such as Nephrin and podocin or activation of cell complementary system causing damage and loss of the negatively charged groups attached to proteins of the GBM.

A diverse metabolic consequence of proteinuria includes, Infection, Hypocalcemia and bone abnormalities, Hypercoagulability and Hypovolemia. During infections patients are more susceptible to Varicella infection along with *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Escherichia coli*. The most common infectious complications are bacterial sepsis, cellulitis, pneumonia, and peritonitis[13]. NS patients are very frequently affected by hyopocalcemia conditions caused by low serum albumin level; on the other hand low bone density and abnormal bone histology are also reported.

Urinary losses of vitamin D–binding proteins with subsequent hypovitaminosis D are one of the reason of such circumstances where reduced in intestinal calcium absorption occurs[14]. It is probable that long duration of either this syndrome or its treatments are the significant risk factors for bone disease in these patients. Venous thrombosis and pulmonary embolism are eminent complications of NS, in these patients urinary loss of anticoagulant proteins, like antithrombin III and plasminogen, beside synchronized raise in clotting factors, particularly factors I, VII, VIII, and X causes conditions such as Hypercoagulability[22].

A report by Mahmoodi et al confirmed the increase in venous thromboembolism (VTE) and arterial thrombotic events together with coronary and cerebrovascular ones with 10 to 15 times higher effect in NS patients compare to normal ones. Acute renal malfunction may point to a fundamental glomerulonephritis however it is more frequent causes of hypovolemia or sepsis. All these consequences finally results to Hypertension connected fluid retention and reduced kidney function which may develop in patients with chronic end stage renal disease[22,23].

Signs and Symptoms

The universal sign and manifestation of NS are swelling, weight gain, fatigue, blood clots, and infections where as some patients may develop kidney failure. Due to increase in protein excretion the urine in the toilet bowel may direct to frothy appearance[25]. This injure where protein usually leak in the urine in more quantity, reduces the total blood protein level. In view of the fact that the protein in the blood prompts the flow of liquid in the bloodstream, due to low protein level this fluid leak out of into tissues, causing swelling, and called edema[15]. The swelling is mainly visible in legs and around eyes when the patients first get up in the morning, in due course of time this swelling may be there all the time and arise in other body parts too along with rapid weight gain[16]. Very less number of patient's are found to have weight loss and this may be due to malnutrition or an principal circumstances, such as badly controlled diabetes mellitus, a chronic viral infection, or cancer. Gradually NS develops in kidney dysfunction, with no or less symptoms at early stage but conversely kidney function continues to worsen finally developing end stage renal disease symptoms, with shortness of breath, weakness and easy fatigability (from anemia) and loss of appetite[17]. The concentration of lipids especially cholesterol and/or triglycerides can become greatly elevated in patients causing increase in risk of coronary artery disease[18]. Patients with NS are at greater risk of blood clots in the veins or arteries which travel through

lungs which leads to dangerous and fatal stage. Patients with severe NS are at increased danger for infections, even though the reasons for this are not well understood. Simple test includes urine visualization where urine foams more than normal because of the quantity of protein in it. Diagnosis may also require a kidney biopsy[29].

Treatment and management

Patients who show positive with signs and symptoms of intense assault are supposed to be treated straight away in an intensive care setting. Current studies confirmed the effectiveness of intravenous theophylline in dropping the period and intense leaky phase of an acute NS. Different vasopressors drugs, for example, 260 mL of a 20% albumin-containing solution, given over 20-60 minutes at intervals determined by clinical status, which have been found to be more successful in maintaining hemodynamic stability among patients[30]. Corticosteroid therapy to counter the inflammatory triggers has now a day's occasionally stopped or minimized as it has been believed that steroids may be damaging to patients who face more frequent attacks and even the affect steroid course in subsequent episodes is uncertain. Many people who go through more severe attacks require mechanical ventilation because of flash pulmonary edema[19,20].

The main goals of cure are to reduce symptoms, avoid complications, and hinder end-stage renal damage. Here are few commonly used treatments enlisted below used to control NS by treating the disorder that is causing it.

- Use of ACE inhibitors i.e. Angiotensin-converting enzyme, to diminish proteinuria, and decrease the threat of evolution to renal disease in persons with NS. In some patient's steroids are given along with ACE inhibitors and maintaining blood pressure at or below 120/80 mmHg to improve response. The suggested dose is unclear; the actual dosage varies from patient to patient. Keep blood pressure at or below 130/80 mmHg to delay kidney damage[21].
- Treatment with corticosteroids remains different among adults and children and is more clearly proved that children respond well compare to grownups, in some patient's it is beneficial while others do not respond at all. Previous studies prove that patients with minor rigorous glomerular changes responded well to steroids treatment. It is recommended that family physicians must consult with nephrologists whether treatment with corticosteroids is sensible, on the contrary the indecisive benefits and chance of adverse effects. Use of alkylating agents has few less proof for improving disease condition, but may be considered for patients who do not respond to corticosteroids[22].
- Studies are going on to inspect the benefits and problems of lipid-lowering treatments in NS. A number of confirmations suggested an enlarged hazard of atherogenesis or myocardial infarction in patients with NS, perhaps connected to increased lipid levels. Lipid lowering treatment is used to treat high cholesterol to decrease the risk of heart and blood vessel problems and for that medication to decrease cholesterol and triglycerides are usually needed[23].
- Along with all these therapies doctors recommended few antibiotic and anticoagulating treatments deepening upon patients response to NS. A low-salt and low-protein

References

1. Arneil, G.C., Clin North Am **18**, 547-59 (1971) .
2. Arneil, G.C., Lam, C.N., Lancet **2**, 819-21 (1966) .
3. ISKDC, J Pediatr **98**, 561-64 (1981) .
4. Smoyer, W.E., Mundel P., J Mol Med (Berl) **76**, 172-83 (1998) .
5. Dantal, J. *et al*., N. Engl. J. Med **330**, 7-14 (1994).
6. Srivastava, T., Simon, S.D., Alon, U.S., Pediatr Nephrol **13**, 13-18 (1999) .
7. Hogg, R.J. *et al*., Pediatrics **105**, 1242-49 (2000) .
8. McEnery, P.T., Strife, C.F., Pediatr Clin North Am **29**, 875-94 (1982) .
9. Bonilla-Felix M. *et al*., Kidney Int **55**, 1885-90 (1999) .
10. Kari J.A., Saudi Med J **23**, 317-21 (2002) .
11. Appel, G.B., Engl J Med **312**, 1544-8 (1985) .
12. Curry, R.C. *et al*., Am J Med **63**, 183-92 (1977) .
13. Mittal, S.K. *et al*., Kidney Int **55**, 1912-9 (1999)
14. Tessitore N.*et al., Nephron* **37**, 153-9 (1984) .
15. Gulati S, *et al., Am J Kidney Dis* **41**, 1163-9 (2003) .
16. Leonard M.B., *et al*., N Engl J Med **351**, 868-75 (2004)
17. Ichikawa, I. et al., J Clin Invest **71**, 91-103 (1983) .
18. Vande Walle J.G. *et al*., Pediatr Nephrol **16**, 283-93 (2001) .
19. Garin, E.H., Pediatr Nephrol **14**, 872- 78 (2000) .
20. Van den Berg, J.G., Weening, J.J., Clin Sci (Lond) **107**, 125-36 (2004) .
21. ISKDC, Kidney Int **13**, 159-65 (1978) .
22. Sorof, J.M. *et al*, Pediatr Nephrol **12**,764-68 (1998).
23. Brater, D.C., N Engl J Med 339, 387-95 (1998).
24. Rybak, L.P., Laryngoscope **95**, 1-14 (1985).
25. Singh, N.C. *et al*., Crit Care Med **2**, 17-21 (1992).